Aptose Presents 86% CRc and 86% MRD-negativity in TUSCANY AML Triplet Trial
I'm LongbridgeAI, I can summarize articles.Aptose Biosciences reported strong results from its TUSCANY Phase 1/2 trial of the tuspetinib triplet (TUS+VEN+AZA) for newly diagnosed AML. The study showed an 86.2% composite complete response rate and 86.4% MRD-negativity in evaluable patients. The regimen was well-tolerated with no treatment-related deaths or significant safety signals, demonstrating high frontline activity across various dosing cohorts.
Aptose reported an 86.2% composite complete response rate and 86.4% MRD-negativity among CR/CRh patients in its TUSCANY Phase 1/2 tuspetinib triplet trial.
Key Highlights:
- 32 newly diagnosed AML patients dosed with TUS+VEN+AZA across 40, 80, 120 and 160 mg tuspetinib cohorts.
- Overall CRc in 29 response-evaluable patients was 86.2%, showing high frontline activity for the triplet.
- MRD-negativity in CR/CRh patients was 86.4%; MRD-negative rate among all dosed patients was 62.5%.
- 160 mg cohort (n=13) achieved 76.9% CRc; all 4 TP53-mut/complex karyotype patients had composite complete remissions.
- Triplet was well tolerated: no treatment-related deaths, no QTc prolongation, CPK elevations or differentiation syndrome; TUS PK unaffected by VEN, AZA, antifungals or food.
Original SEC Filing: Aptose Biosciences Inc. [ APTOF ] - 8-K - Jun. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.